HOME >> MEDICINE >> NEWS
Drug combination proves effective against myeloma in Phase I trial

BOSTONTwo "new generation" drugs for the bone marrow cancer multiple myeloma may work even better together than they do individually, according to the results of a multicenter Phase I clinical trial to be presented by Dana-Farber Cancer Institute scientists at the annual meeting of the American Society of Hematology in Orlando, Fla.

The trial the first and largest reported to date to test the drugs bortezomib (Velcade) and lenalidomide (Revlimid) in combination involved 38 myeloma patients whose disease had recurred after previous treatment and was progressing despite other therapies.

Participants were divided into groups that received successively higher doses of the drugs. Some also received dexamethasone, a standard myeloma medication which adds to the effects of both bortezomib and lenalidomide, if the combination alone no longer controlled their disease.

The researchers, led by Paul Richardson, MD, and Ken Anderson, MD, of Dana-Farber, found that 58 percent of 36 evaluable patients responded to lenalidomide and bortezomib, including six percent who had complete remission, despite being heavily pre-treated and, in most cases, having received both classes of drug before. The median length of remission was six months, with some patients having disease control for up to two and a half years. The combined therapy also produced only mild fatigue or peripheral neuropathy (nerve damage signaled by tingling or numbness), researchers found. Patients who received dexamethasone because their disease continued to progress on the drug combination found the additional drug tolerable, and it produced a response or disease stabilization in about three quarters of them.

"It is remarkable to see the combination prove both tolerable and engender such durable responses in resistant disease," Richardson says. "We are hopeful that this combination will prove to be a key therapeutic backbone in improving outcomes for our patients, both earl
'"/>

Contact: Teresa Herbert
teresa_herbert@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
11-Dec-2006


Page: 1 2

Related medicine news :

1. Phase II study shows combination improves survival of metastatic melanoma patients
2. Certain combination therapy found more effective for treating malaria in African children
3. To get blood pressure under control, combination of medicines may be best
4. Drug/intervention combinations offer benefit in severe CVD
5. Scripps research combination therapy obliterates new vessel growth in tumors and retinopathy
6. Drug combination slows progression of treatment resistant bone marrow cancer
7. Drug combination could reduce risk of severe asthma attacks
8. Transplant patients keep their new kidney longer with a CellCept-based drug combination
9. Rheumatoid arthritis patients can benefit from Enbrel in combination with methotrexate
10. New combination therapy after surgery improves survival for pancreatic cancer patients
11. International study launched testing new drug combination to cut cardiovascular disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/11/2019)... ... 11, 2019 , ... Executives at health systems and hospitals across America are ... over the past several years has been intense. For professionals and organizations that struggle ... America will depend largely on how these executives respond. Will they have the tools ...
(Date:9/11/2019)... ... September 10, 2019 , ... ... facing the ever-changing corporate landscape, Mediaplanet today announces the launch of its ... topics ranging from the importance of candid one-on-one conversations, ideas for improving ...
(Date:9/9/2019)... ... September 09, 2019 , ... ... Dentistry in Cornelius, NC, now welcome individuals with tooth loss in Davidson, NC ... with patients who have single or multiple missing teeth and want the advantages ...
(Date:9/9/2019)... ... September 09, 2019 , ... On September 6, 2019, ... on a diabetes-language movement (#LanguageMatters) to include oral and written language. The organization ... stigma, respectful and inclusive, empowering, and person-centered (to include care that is respectful ...
(Date:9/8/2019)... ... 2019 , ... The Southern Illinois University Edwardsville School of ... reached an all-time high with 1,778 students. , The SON’s enrollment features ... students. The total does not include an additional 30 undeclared graduate students, who ...
Breaking Medicine News(10 mins):
(Date:9/14/2019)... ... 14, 2019 , ... On September 11, 2019, after a ... in Middlesex County found Johnson & Johnson liable for causing the Plaintiffs’ cancers. ... by asbestos-containing J&J talc products. , A unanimous jury found that ...
(Date:9/12/2019)... ... September 12, 2019 , ... iPatientCare, a ... practice management, and patient engagement solutions, announced today the participation of Amazon ... (NUCON) 2019 . The annual conference features informative sessions about upcoming enhancements, ...
(Date:9/11/2019)... ... September 12, 2019 , ... Understanding the Drug ... FDAnews Webinar, Thursday, Sept. 26, 2019, 1:30-3:00 p.m. EDT, https://www.fdanews.com/understanding-the-dscsa , ... Is the company clear on nuances of the guidelines regulating the drug supply ...
Breaking Medicine Technology:
Cached News: